Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction

• Of 7944 patients with STEMI, 296 (3.7%) developed NEW-AF within 30 days of STEMI. following STEMI was associated poor long-term prognostic outcomes. OAC therapy in reduced mortality. may benefit from addition to usual antithrombotic treatment Future monitoring after is pivotal improve prognosis New-onset atrial fibrillation (NEW-AF) ST-segment elevation myocardial infarction (STEMI) a common complication, but the true impact unknown. Additionally, optimal among warranted. A large cohort consecutive treated percutaneous coronary intervention were identified using Eastern Danish Heart Registry 1999-2016. Medication and end points retrieved nationwide registries. defined as diagnosis AF Patients without history alive discharge included. Incidence rates calculated multivariate analyses performed determine association between mortality, incidence ischemic stroke, re-MI, bleeding leading hospitalization, comparative effectiveness on these NEW-AF. increased mortality (adjusted HR 1.48, 95% CI 1.20-1.82, P <.001) risk hospitalization 1.36, 1.00-1.85, =.050), non-significant stroke 1.45, 0.96-2.19, =.08) re-MI 1.14, 0.86-1.52, =.35) median follow-up 5.8 years. In patients, 38% received therapy, which 0.69, 0.47-1.00, =.049). Treatment